Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)

Description

To develop a database of medical information about patients with MLA in an effort to increase our understanding of the characteristics of MLA, which is the rarest form of endometrial carcinoma.

Conditions

Mesonephric-like Adenocarcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

To develop a database of medical information about patients with MLA in an effort to increase our understanding of the characteristics of MLA, which is the rarest form of endometrial carcinoma.

Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)

Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)

Condition
Mesonephric-like Adenocarcinoma
Intervention / Treatment

-

Contacts and Locations

Houston

MD Anderson Cancer Center, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Adult patients with a diagnosis of gynecologic mesonephric-like adenocarcinoma (MLA).
  • 2. Patients can also be diagnosed with mesonephric adenocarcinoma (MA) or patients with mesonephric and mesonephric-like carcinosarcomas.
  • 3. Patients who are receiving or have received treatment at any facility, including but not limited to MD Anderson Cancer Center are eligible.
  • 4. Patients may be residents of any country and be of any ethnic background.
  • 5. Patients who request to participate in the registry, regardless of the method by which they learned of it, are eligible to participate.
  • 6. Patients who do not speak English can be eligible if accompanied by an institutional interpreter.
  • 1. Patients with other subtypes of EACs.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

M.D. Anderson Cancer Center,

Jeffrey How, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

2037-12-28